Praxis Precision Medicines (PRAX) is a Boston-based, clinical-stage neuroscience company developing treatments for central nervous system disorders, with two late-stage candidates under FDA review: ulixacaltamide for essential tremor and relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies. Shares changed hands at $310.32 around midday, a gain of $5.13, or 1.68%, versus the previous session's close of $305.19 — confirming an upward move. The immediate driver was a Wells Fargo upgrade to Overweight with a sharply higher $509 price target, though the stock had already pared a gain of more than 7% recorded shortly after the opening bell.
Wells Fargo shifted its stance to Overweight from Equal Weight and lifted its valuation target to $509 from $343 — an increase of nearly 50% and a level roughly 64% above today's trading range. The change is notable because the firm had been at Hold as recently as Nov. 10, meaning the upgrade reflects a rapid reassessment rather than a long-held view. The note leaned on the company's Nov. 12 investor day, citing stronger confidence in the durability of the ulixacaltamide Essential3 data and in the regulatory path toward two near-term approval decisions. Analyst upgrades of this magnitude typically reset the debate on valuation, which is what pulled buyers in at the open. Wall Street's consensus rating remains Buy, with a wide dispersion of targets reflecting differing assumptions on launch timing and label breadth.
The upgrade did not emerge in a vacuum. At its investor day, Praxis disclosed that FDA-requested sensitivity analyses of the Essential3 primary endpoint were consistent with the original result, addressing a key bear concern. The company also presented updated open-label extension data for relutrigine showing an 86% reduction from baseline in seizures for SCN2A and SCN8A patients over 18 months, and outlined plans to study ulixacaltamide in Parkinson's disease, restless legs syndrome and autism spectrum disorder starting in 2027. Those disclosures are the substance behind the price rally, even if today's trading was triggered by the rating change.
The shape of the session matters as much as the headline percentage. After opening at $309.24, shares spiked to $326.84, a gain of more than 7%, then faded steadily through the morning to $310.32, leaving the session low at $308.57. The retreat stalled just below the 200-day moving average near $315 — a level the stock has struggled to reclaim — and came after a one-month advance of roughly 26% from mid-October closes near $242. That pattern is consistent with profit-taking into strength rather than a deterioration in the news itself.
Volume was heavy at the open but not exceptional overall: roughly 150,000 shares had traded by midday against a three-month average of about 471,000 per full session, implying a pace below normal rather than a volume surge. The stock's move diverged from the tape — biotech sector ETFs were flat to marginally lower and the S&P 500 was down about 1% — confirming a company-specific catalyst. Technically, shares remain above their 50-day moving average around $287 but below the 200-day line near $315, leaving the stock boxed between those levels. The 52-week range spans $160.11 to $392.70, a reminder of how wide this name's swings have been.
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. This session earns 25 out of 100. The verified catalyst — a sell-side upgrade with a substantially higher target — is moderate in weight: it changes sentiment and valuation framing but not the underlying regulatory or clinical facts for a company already valued above $8.5 billion. The move itself was unremarkable; at 1.68% it was only about 0.6x the stock's typical 2.8% daily swing, and 32 of the past 60 sessions produced equal or larger changes. Moderate news plus an ordinary move for a volatile biotech lands in the low-to-mid 20s.
Three scheduled events dominate the calendar. Relutrigine faces a PDUFA target action date of Dec. 27, 2026 — the first potential approval and the nearer-term binary. EMERALD topline results in broad developmental and epileptic encephalopathies are expected before year-end and could support a broader label and a larger commercial opportunity. Ulixacaltamide, the essential tremor candidate, has a PDUFA date of Jan. 29, 2027, with launch infrastructure already being built. Full-year financial results are expected in February. Risks include potential regulatory delays, DEA scheduling of ulixacaltamide that could postpone commercial shipments, label restrictions, first-launch execution, and continued cash consumption, though $1.3 billion in cash and investments is guided to fund operations into 2028.
Tickeron offers hundreds of AI trading bots that cover thousands of tickers, but only the strongest performers under current market conditions make it into the curated Trending AI Robots section. The bots differ by strategy, timeframe, performance metrics and the symbols they trade, so the list offers a useful cross-section of what is working right now. Reviewing the leaders can help traders compare approaches and identify strategies worth tracking through the next catalyst window.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Moving Average Convergence Divergence (MACD) for PRAX turned positive on October 20, 2026. Looking at past instances where PRAX's MACD turned positive, the stock continued to rise in 41 of 43 cases over the following month. The odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on PRAX as a result. In 84 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
PRAX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PRAX crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +1.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRAX advanced for three days, in 258 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Aroon Indicator entered an Uptrend today. In 180 of 202 cases where PRAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
The 10-day RSI Indicator for PRAX moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In 31 of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 54 of 63 cases where PRAX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
The 50-day moving average for PRAX moved below the 200-day moving average on October 22, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
PRAX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.780) is normal, around the industry mean (3.596). P/E Ratio (-21.421) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. PRAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology